Limantrafin Drug Asset Due Diligence Report 2026

This Limantrafin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Limantrafin can convert its Small molecule drug profile and Notch-1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Limantrafin (query alias: Limantrafin)
Modality / target	Small molecule drug; Notch-1; NOTCH1 inhibitors
Highest global status	Phase 2
Originator	Cellestia Biotech AG
Active developers	Cellestia Biotech AG

The MCP disease footprint includes Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Adenoid Cystic Carcinoma, Graft vs Host Disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05774899	Phase 1/2	Recruiting	32	Primary endpoint not disclosed in English source
NCT05464836	Phase 2	Terminated	2	Primary endpoint not disclosed in English source
NCT04714619	Phase 2	Terminated	2	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase II Study to Evaluate Safety and Efficacy of CB-103 in Combination With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)

Phase 2; n=2; evaluation: Not stated in English source. Reported fields: PD = 1 Pts

Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers.

Phase 1; n=41; evaluation: Positive. Reported fields: DLT = One DLT (asymp ~ matic grade (G) 3 GGT increase) was observed at the highest dose (600mg).

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Limantrafin addresses Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Adenoid Cystic Carcinoma, Graft vs Host Disease. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 2 matched transaction record(s) under the scope “target-level comparable: Notch-1.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: Notch-1 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2017-12-06	Juno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center	Phase 2	Financial terms not disclosed
2017-07-11	OncoMed acknowledged that its cancer candidate tarextumab—part of a collaboration with GlaxoSmithKline—failed a Phase II combination treatment trial	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods of use for quinazoline compounds”. The milestone feed surfaced a patent-application signal described as “Methods of use for aza-quinazoline compounds”. The milestone feed surfaced a patent-application signal described as “Novel culture conditions for clonal expansion of nephron progenitor cells, generation of nephron organoids, and rapid and scalable modeling of polycystic kidney disease”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO